SironRX Therapeutics is a private clinical-stage company developing novel therapies for dermal wound repair with a specific focus on mitigating scar formation and accelerating wound healing.  Through its lead product, JVS-100, SironRX is targeting these indications with significant market potential and high-unmet medical need.

JVS-100 is a clinically tested, non-viral DNA plasmid that encodes stromal cell-derived factor-1 (SDF-1). SDF-1 is naturally produced by the human body in response to tissue injury and activates the body’s own native repair processes, recruiting endogenous stem cells to the damaged region and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved across tissue types.

SironRX is currently enrolling in a double-blind, placebo-controlled, randomized clinical trial in surgical wounds.  The Company is evaluating JVS-100 drug safety and its ability of to reduce scar formation and accelerate wound repair. Previous clinical studies with JVS-100 have demonstrated the drug is well tolerated and safe.